Prognostic significance of left ventricular mass change during treatment of hypertension.

CONTEXT Increased baseline left ventricular (LV) mass predicts cardiovascular (CV) complications of hypertension, but the relation between lower LV mass and outcome during treatment for hypertension is uncertain. OBJECTIVE To determine whether reduction of LV mass during antihypertensive treatment modifies risk of major CV events independent of blood pressure change. DESIGN, SETTING, AND PARTICIPANTS Prospective cohort substudy of the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) randomized clinical trial, conducted from 1995 to 2001. A total of 941 prospectively identified patients aged 55 to 80 years with essential hypertension and electrocardiographic LV hypertrophy had LV mass measured by echocardiography at enrollment in the LIFE trial and thereafter were followed up annually for a mean (SD) of 4.8 (1.0) years for CV events. MAIN OUTCOME MEASURES Composite end point of CV death, fatal or nonfatal myocardial infarction, and fatal or nonfatal stroke. RESULTS The composite end point occurred in 104 patients (11%). The multivariable Cox regression model showed a strong association between lower in-treatment LV mass index and reduced rate of the composite CV end point (hazard ratio [HR], 0.78 per 1-SD (25.3) decrease in LV mass index; 95% confidence interval [CI], 0.65-0.94; P = .009) over and above that predicted by reduction in blood pressure. There were parallel associations between lower in-treatment LV mass index and lower CV mortality (HR, 0.62; 95% CI, 0.47-0.82; P = .001), stroke (HR, 0.76; 95% CI, 0.60-0.96; P = .02), myocardial infarction (HR, 0.85; 95% CI, 0.62-1.17, P = .33), and all-cause mortality (HR, 0.72; 95% CI, 0.59-0.88, P = .002), independent of systolic blood pressure and assigned treatment. Results were confirmed in analyses adjusting for additional CV risk factors, electrocardiographic changes, or when only considering events after the first year of study treatment. CONCLUSION In patients with essential hypertension and baseline electrocardiographic LV hypertrophy, lower LV mass during antihypertensive treatment is associated with lower rates of clinical end points, additional to effects of blood pressure lowering and treatment modality.

[1]  M. Nieminen,et al.  Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. , 2004, JAMA.

[2]  M. Nieminen,et al.  Regression of Hypertensive Left Ventricular Hypertrophy by Losartan Compared With Atenolol: The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Trial , 2004, Circulation.

[3]  M. Nieminen,et al.  1009-166 Pulse pressure as cardiovascular risk marker during losartan or atenolol based therapy in hypertensive patients with electrocardiographic left ventricular hypertrophy (the LIFE trial) , 2004 .

[4]  M. Nieminen,et al.  Regression of Electrocardiographic Left Ventricular Hypertrophy by Losartan Versus Atenolol: The Losartan Intervention For Endpoint reduction in hypertension (LIFE) Study , 2003, Circulation.

[5]  S. Yusuf,et al.  Reduction of Cardiovascular Risk by Regression of Electrocardiographic Markers of Left Ventricular Hypertrophy by the Angiotensin-Converting Enzyme Inhibitor Ramipril , 2001, Circulation.

[6]  B. Howard,et al.  Reference values for echocardiographic measurements in urban and rural populations of differing ethnicity: the Strong Heart Study. , 2001, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[7]  P. Okin,et al.  Prognostic implications of left ventricular hypertrophy. , 2001, American heart journal.

[8]  M. Nieminen,et al.  Echocardiographic Left Ventricular Geometry in Hypertensive Patients with Electrocardiographic Left Ventricular Hypertrophy: The LIFE Study , 2001, Blood pressure.

[9]  R. Devereux,et al.  Effect of Type 2 Diabetes Mellitus on Left Ventricular Geometry and Systolic Function in Hypertensive Subjects: Hypertension Genetic Epidemiology Network (HyperGEN) Study , 2001, Circulation.

[10]  R. Devereux,et al.  Reliability of echocardiographic assessment of left ventricular structure and function: the PRESERVE study. Prospective Randomized Study Evaluating Regression of Ventricular Enlargement. , 1999, Journal of the American College of Cardiology.

[11]  M. Nieminen,et al.  Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension. , 1998, Hypertension.

[12]  G. Reboldi,et al.  Prognostic significance of serial changes in left ventricular mass in essential hypertension. , 1998, Circulation.

[13]  B. Howard,et al.  Relations of left ventricular mass to demographic and hemodynamic variables in American Indians: the Strong Heart Study. , 1997, Circulation.

[14]  M. Nieminen,et al.  The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group. , 1997, American journal of hypertension.

[15]  P. Okin,et al.  Regression of left ventricular hypertrophy as a surrogate end-point for morbid events in hypertension treatment trials , 1996, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[16]  D. Rizzoni,et al.  Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment , 1995, Journal of hypertension.

[17]  Daniel L. McGee,et al.  The relative effects of left ventricular hypertrophy, coronary artery disease, and ventricular dysfunction on survival among black adults. , 1995, JAMA.

[18]  P. Kligfield,et al.  Electrocardiographic identification of increased left ventricular mass by simple voltage-duration products. , 1995, Journal of the American College of Cardiology.

[19]  G. Reboldi,et al.  Ambulatory blood pressure. An independent predictor of prognosis in essential hypertension. , 1994, Hypertension.

[20]  D. Levy,et al.  Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. , 1994, Circulation.

[21]  M. Alderman,et al.  Role of Preclinical Cardiovascular Disease in the Evolution From Risk Factor Exposure to Development of Morbid Events , 1993, Circulation.

[22]  J. Ghali,et al.  The Prognostic Role of Left Ventricular Hypertrophy in Patients with or without Coronary Artery Disease , 1992, Annals of Internal Medicine.

[23]  A. Yurenev,et al.  Management of essential hypertension in patients with different degrees of left ventricular hypertrophy. Multicenter trial. , 1992, American journal of hypertension.

[24]  J. Laragh,et al.  Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. , 1991, Annals of internal medicine.

[25]  D E Manyari,et al.  Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. , 1990, The New England journal of medicine.

[26]  R. Collins,et al.  Blood pressure, stroke, and coronary heart disease Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context , 1990, The Lancet.

[27]  N. Reichek,et al.  Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. , 1989, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[28]  J. Cutler,et al.  Electrocardiographic left ventricular hypertrophy and effects of antihypertensive drug therapy in hypertensive participants in the Multiple Risk Factor Intervention Trial. , 1989, The American journal of cardiology.

[29]  N. Reichek,et al.  Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. , 1986, The American journal of cardiology.

[30]  MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party. , 1985, British medical journal.

[31]  THE AUSTRALIAN THERAPEUTIC TRIAL IN MILD HYPERTENSION Report by the Management Committee , 1980, The Lancet.

[32]  A. DeMaria,et al.  Recommendations Regarding Quantitation in M-Mode Echocardiography: Results of a Survey of Echocardiographic Measurements , 1978, Circulation.

[33]  M. Gardner,et al.  Some effects of within-person variability in epidemiological studies , 1973 .

[34]  Liakishev Aa.  [Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol. Results of LIFE study]. , 2003, Kardiologiia.

[35]  R. Devereux,et al.  Impact of different partition values on prevalences of left ventricular hypertrophy and concentric geometry in a large hypertensive population : the LIFE study. , 2000, Hypertension.

[36]  J. Schwartz,et al.  Association of carotid atherosclerosis and left ventricular hypertrophy. , 1995, Journal of the American College of Cardiology.

[37]  L. Rossi,et al.  Prognostic value of left ventricular mass in uncomplicated acute myocardial infarction and one-vessel coronary artery disease. , 1994, The American journal of cardiology.

[38]  L. Wilkins.  Five-year findings of the Hypertension Detection and Follow-up Program. Prevention and reversal of left ventricular hypertrophy with antihypertensive drug therapy. Hypertension Detection and Follow-up Program Cooperative Group. , 1985, Hypertension.

[39]  M. Nieminen,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .